December 18th 2024
The 2 novel vaccine candidates each combine a Sanofi licensed influenza vaccine with the Novavax adjuvanted recombinant COVID-19 vaccine.
Your daily dose of the clinical news you may have missed.
November 12th 2024
The FDA cleared Novavax to start enrolling the planned phase 3 trial after a safety concern was found to be unrelated to the combination vaccine.
November 11th 2024
Find details on the surge in US pertussis cases, the first self-administered flu vaccine, and study findings underscoring the evolving nature of long COVID.
Insights on how to manage the "triple threat" of flu, RSV, and COVID-19 this season.